tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Next Science Reports Decline in Sales and Asset Sale Approval

Story Highlights
  • Next Science saw a 7% drop in product sales, with direct sales of XPERIENCE up 54%.
  • Shareholders approved the asset sale to OSARTIS GmbH, impacting the company’s future operations.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Next Science Reports Decline in Sales and Asset Sale Approval

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Next Science Ltd ( (AU:NXS) ) just unveiled an update.

Next Science Limited reported its half-year financial results for the period ending June 30, 2025, showing a 7% decline in product sales to US$10.5 million. Despite a 54% increase in direct sales of XPERIENCE, overall direct product sales fell by 20%. The company improved its operating expenses by 17%, resulting in a reduced adjusted EBITDA loss of US$2.8 million. The shareholders approved the sale of the majority of the Group’s assets to OSARTIS GmbH, expected to complete by mid-September 2025, which will not affect the company’s capital structure.

The most recent analyst rating on (AU:NXS) stock is a Buy with a A$0.40 price target. To see the full list of analyst forecasts on Next Science Ltd stock, see the AU:NXS Stock Forecast page.

More about Next Science Ltd

Next Science Limited is a medical technology company focused on commercializing its proprietary XBIO suite of products, aimed at reducing the impact of biofilm-based infections on human health.

Average Trading Volume: 558,373

Technical Sentiment Signal: Sell

Current Market Cap: A$42.43M

For detailed information about NXS stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1